$EARS #Auris Medical Holding AG Auris Medical Holding - AM-201 data expected in early May: Auris has announced that final data from its 80-subject AM-201 Phase Ib trial for olanzapine-induced weight gain and somnolence should be available… https://t.co/biOdJhPNgb #equity #stocks https://t.co/xUM97JT4ji